Fintel reports that on April 28, 2023, Morgan Stanley maintained coverage of Ascendis Pharma A (NASDAQ:ASND) with a Equal-Weight recommendation.
Analyst Price Forecast Suggests 107.63% Upside
As of April 24, 2023, the average one-year price target for Ascendis Pharma A is 145.26. The forecasts range from a low of 82.82 to a high of $204.75. The average price target represents an increase of 107.63% from its latest reported closing price of 69.96.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Ascendis Pharma A is 152MM, an increase of 197.91%. The projected annual non-GAAP EPS is -9.74.
What is the Fund Sentiment?
There are 435 funds or institutions reporting positions in Ascendis Pharma A. This is an increase of 19 owner(s) or 4.57% in the last quarter. Average portfolio weight of all funds dedicated to ASND is 0.73%, an increase of 5.10%. Total shares owned by institutions decreased in the last three months by 0.47% to 81,678K shares. 
The put/call ratio of ASND is 0.42, indicating a bullish outlook.
What are Other Shareholders Doing?
Ra Capital Management holds 6,957K shares representing 12.38% ownership of the company. In it's prior filing, the firm reported owning 7,568K shares, representing a decrease of 8.78%. The firm increased its portfolio allocation in ASND by 3.37% over the last quarter.
Artisan Partners Limited Partnership holds 6,920K shares representing 12.31% ownership of the company. In it's prior filing, the firm reported owning 7,149K shares, representing a decrease of 3.31%. The firm increased its portfolio allocation in ASND by 15.14% over the last quarter.
Baker Bros. Advisors holds 4,955K shares representing 8.81% ownership of the company. In it's prior filing, the firm reported owning 4,853K shares, representing an increase of 2.06%. The firm increased its portfolio allocation in ASND by 10.74% over the last quarter.
Price T Rowe Associates holds 3,710K shares representing 6.60% ownership of the company. In it's prior filing, the firm reported owning 3,875K shares, representing a decrease of 4.45%. The firm increased its portfolio allocation in ASND by 11.19% over the last quarter.
Janus Henderson Group holds 3,644K shares representing 6.48% ownership of the company. In it's prior filing, the firm reported owning 3,837K shares, representing a decrease of 5.29%. The firm increased its portfolio allocation in ASND by 7.10% over the last quarter.
Ascendis Pharma A Background Information
(This description is provided by the company.)
Ascendis Pharma is applying its innovative TransCon technologies to build a leading, fully integrated biopharmaceutical company focused on making a meaningful difference in patients' lives. Guided by its core values of patients, science and passion, the company utilizes its TransCon technologies to create new and potentially best-in-class therapies.
See all Ascendis Pharma A regulatory filings.This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
